Rite Aid reports results for 3Q 2008
CAMP HILL, Pa. Rite Aid delivered an early Christmas present to investors Thursday, reporting an adjusted EBITDA increase of 8.5% on higher gross margin rates and improved cost controls and, for the first time since its acquisition of Brooks/Eckerd, positive front-of-store sales growth across its Brooks/Eckerd store base.
Rite Aid reported revenues of $6.5 billion, down 0.5%—primarily as a result of closing 229 stores—and a net loss of $243.1 million ($0.30 per diluted share) for its fiscal third quarter ended Nov. 29. The adjusted EBITDA of $252 million, representing 3.9% of revenues, significantly exceeded expectations of Wall Street analysts, which hovered around $205.2 million.
“I am pleased to report a significant improvement in our operating results this quarter with adjusted EBITDA up 8.5%,” stated Mary Sammons, Rite Aid chairman and chief executive officer. “With the Brooks/Eckerd integration complete, our team has been totally focused on delivering profitable sales and taking unnecessary costs out of the business, and it showed. Same-store sales were up, with pharmacy sales in core Rite Aid stores especially strong despite an industrywide slowdown in prescription growth. Our gross profit rate improved, and our cost savings initiatives intensified in the quarter. Improving operational efficiency is a top priority, and we expect to see even greater benefits from these initiatives going forward.”
And things are looking up for the chain. The largest variable in the near future will be sales, explained John Standley, president and chief operating officer at Rite Aid, during a conference call with analysts Thursday morning. Given that sales improvements can be realized through continued optimal cost controls and the blocking and tackling of retailing—in other words merchandising and marketing—Rite Aid is not in an altogether bad position. “I remain confident,” he said. “We have a lot of momentum here,” he added. “We’re seeing a very nice month in pharmacy [so far in December] across both Brooks/Eckerd and core stores.”
“Although sales in 3Q, especially in November, were weaker than we had expected, management indicated that seasonal inventory was bought carefully, and mark downs began as planned before Thanksgiving,” noted Meredith Adler, research analyst of Barclays Capital. “In addition, the company indicated that it had not been more promotional during the quarter than previously and is still focused on generating profitable sales.”
“The business environment is likely to be even more challenging than it is today,” Sammons said, but with the continued improvements in cost controls and quarter-over-quarter increases in Brooks/Eckerd sales results, Rite Aid will likely to continue to improve operational results as the chain enters 2009.
Those greater cost controls and incremental improvements in operations will help deliver on the chain’s guidance with regard to total sales and adjust EBITDA, but current sales trends and the tough economy has prompted the chain to lower its guidance for same store sales and increase projected net loss for fiscal 2009, which ends Feb. 28.
Total sales projects remain between $26 billion and $26.5 with adjusted EBITDA between $950 million and $1 billion. Same-store sales are now expected to improve between 0.5% and 1.5% over fiscal 2008 as compared to previous guidance of a 1.5% to 3% increase. And net loss for fiscal 2009 is expected to be between $593 million and $773 million, or a loss per diluted share of $0.74 to $0.95, compared to previous guidance of $445 million to $535 million or a loss per diluted share of $0.56 to $0.67. The company continues to expect capital expenditures, excluding approximately $200 million of proceeds from sale and leaseback transactions, to be approximately $550 million.
Overall same-store sales for the No. 3 drug store retailer were up 1.4% year-over-year, consisting of a 2.3% increase across the front-end and a 1% increase in the pharmacy. However, the number of prescriptions filled across the chain fell approximately 1%, suggesting that the Brooks/Eckerd pharmacy operations may be losing marketshare. Rite Aid’s core stores filled more prescriptions in this quarter compared to last year, the chain reported.
Excluding the acquired Brooks Eckerd stores, same-store sales for the 13-week third quarter increased 2.6% over the prior-year period with front-end increasing 1.9% and pharmacy growing 3%. Same-store sales at the former Brooks/Eckerd operations fell 1% over the period, The chain’s 3.7% increase across the front-end in its Brooks/Eckerd operations is a sea change from what the chain recorded across its second quarter, which was a decline of 2.7%. Pharmacy same-store sales improved as well, with a 2.6% decline in comparable sales over the third quarter, compared to a 4.6% decline across the second quarter.
Prescription sales accounted for 67.9% of total sales, and third-party prescription sales represented 96.4% of pharmacy sales.
In the third quarter, the company opened 13 stores, relocated 23 stores, remodeled 11 stores and closed 29 stores. Stores in operation at the end of the third quarter totaled 4,914.
Aurora to support Concordia University School of Pharmacy
MEQUON, Wis. Milwaukee-based Aurora Health Care will provide program support for Concordia University Wisconsin’s upcoming School of Pharmacy, Concordia officials announced Wednesday.
“It is important that we extend our resources to help ensure there are more opportunities to educate and train pharmacists in Wisconsin,” Aurora president and chief executive officer Nick Turkal said in a statement. “We have a longstanding commitment to find solutions to the challenges of health care, including the need to fill those positions where there are workforce shortages.”
One part of Aurora’s support involves letting Concordia pharmacy students work at Aurora pharmacies while its pharmacists serve as instructors at the school.
“We are excited with the news that Aurora Health Care will be partnering with us,” Concordia School of Pharmacy executive dean Curt Gielow said.
Concordia has raised $3 million of the $20 million it needs to build the pharmacy school by the 2011-2012 academic year, including $17 million to construct the building, Gielow said. The school will accept 50 to 75 students per class and train practitioner pharmacists to work in urban and rural areas.
The academic program will include a standard “2+4” program, comprising a two-year pre-pharmacy program and a four-year professional program, as well as a four-year bachelor of science degree program in pharmaceutical sciences.
Milwaukee is one of the largest cities in the country without a local pharmacy school.
FDA grants waivers to Abaxis for point-of-care analyzers
UNION CITY, Calif. The Food and Drug Administration has given blood-analysis system manufacturer Abaxis a waived status for two analytes, creatine kinase and phosphorus, when used by healthcare professionals with the Piccolo and Piccolo Xpress point-of-care analyzers, Abaxis said last week.
The company said Thursday that as a result of the waived status, healthcare professionals have better access to the Renal Function and MetLyte 8 panels and can conduct this testing at the point-of-care under a certificate of waiver.
“The waiver of these two panels bolsters our already comprehensive offering to healthcare professionals, enabling them to conduct important testing at the point of care in order to manage patients in real time,” Abaxis chairman and chief executive officer Clint Severson said in a statement. “We believe rapid and accurate diagnostic testing can lead to improved patient care while reducing some of the administrative burden healthcare practices face on a daily basis.”
The panels are respectively used to determine renal function status and to assess several metabolic conditions across several medical specialties, including pediatrics and cardiology.